Combining Antidepressants vs Antidepressant Monotherapy for Treatment of Patients With Acute Depression

Effectiveness of mirtazapine as add-on to paroxetine v. paroxetine or mirtazapine monotherapy in patients with major depressive disorder with early non-response to paroxetine: a two-phase, multicentre, randomized, double-blind clinical trial

(2020) Le Xiao et al.   PSYCHOLOGICAL MEDICINE

Effects of concurrent treatment with amitriptyline hydrochloride tablets and fluoxetine hydrochloride on therapeutic indicator levels in patients with depression

(2019) Yin Jie et al.   TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH

Optimising first- and second-line treatment strategies for untreated major depressive disorder — the SUN☺D study: a pragmatic, multi-centre, assessor-blinded randomised controlled trial

(2018) Tadashi Kato et al.   BMC Medicine

Trajectories of Acute Antidepressant Efficacy

(2018) Jonathan Henssler et al.   JOURNAL OF CLINICAL PSYCHIATRY

Dose Increase Versus Unchanged Continuation of Antidepressants After Initial Antidepressant Treatment Failure in Patients With Major Depressive Disorder

(2018) Lena Rink et al.   JOURNAL OF CLINICAL PSYCHIATRY

Switching the Antidepressant After Nonresponse in Adults With Major Depression

(2018) Tom Bschor et al.   JOURNAL OF CLINICAL PSYCHIATRY

Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis

(2018) Andrea Cipriani et al.   LANCET

Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis

(2018) Rebecca Strawbridge et al.   BRITISH JOURNAL OF PSYCHIATRY

Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR)

(2018) David S Kessler et al.   BMJ-British Medical Journal

Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment

(2017) Somaia Mohamed et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Non response at week 4 as clinically useful indicator for antidepressant combination in major depressive disorder. A sequential RCT

(2017) Masaki Kato et al.   JOURNAL OF PSYCHIATRIC RESEARCH

Standardized mean differences cause funnel plot distortion in publication bias assessments

(2017) Peter-Paul Zwetsloot et al.   eLife

Combining Antidepressants in Acute Treatment of Depression: A Meta-Analysis of 38 Studies Including 4511 Patients

(2016) Jonathan Henssler et al.   CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE

Duloxetine-bupropion combination for treatment-resistant atypical depression: A double-blind, randomized, placebo-controlled trial

(2014) Michele Fornaro et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Combination antidepressant therapy for major depressive disorder: Speed and probability of remission

(2013) Jonathan W. Stewart et al.   JOURNAL OF PSYCHIATRIC RESEARCH

Efficacy and safety of add on low-dose mirtazapine in depression

(2012) DineshK Badyal et al.   INDIAN JOURNAL OF PHARMACOLOGY

Antidepressant monotherapy compared with combinations of antidepressants in the treatment of resistant depressive patients: A randomized, open-label study

(2012) Martin Bares et al.   INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE

Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and Long-Term Outcomes of a Single-Blind Randomized Study

(2011) A. John Rush et al.   AMERICAN JOURNAL OF PSYCHIATRY

Bupropion as an Augmenting Agent in Patients of Depression with Partial Response

(2011) Gaurav Gulrez et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

A Pilot Study of the Efficacy and Safety of Paroxetine Augmented With Risperidone, Valproate, Buspirone, Trazodone, or Thyroid Hormone in Adult Chinese Patients With Treatment-Resistant Major Depression

(2011) Yiru Fang et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone

(2010) M. Ferreri et al.   ACTA PSYCHIATRICA SCANDINAVICA

Comparisons of the Efficacy and Tolerability of Extended-Release Venlafaxine, Mirtazapine, and Paroxetine in Treatment-Resistant Depression

(2010) Yiru Fang et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Combination of Antidepressant Medications From Treatment Initiation for Major Depressive Disorder: A Double-Blind Randomized Study

(2009) Pierre Blier et al.   AMERICAN JOURNAL OF PSYCHIATRY

Mirtazapine and paroxetine in major depression: A comparison of monotherapy versus their combination from treatment initiation

(2009) Pierre Blier et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Pharmacokinetics and Efficacy of Fluvoxamine and Amitriptyline in Depression

(2009) Sandra Vezmar et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder

(2009) Andrew F. Leuchter et al.   PSYCHIATRY RESEARCH

Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in Major Depressive Disorder: Results of the BRITE-MD study

(2009) Andrew F. Leuchter et al.   PSYCHIATRY RESEARCH

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   PLOS MEDICINE

Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration

(2008) Irving Kirsch et al.   PLOS MEDICINE